<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200219046552N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-03-29</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of local corticosteroid injection and high-intensity laser outcomes in moderate carpal tunnel syndrome (CTS)</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of local corticosteroid injection and high-intensity laser outcomes in moderate carpal tunnel syndrome (CTS)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-04-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>126</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/46465</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients were randomly divided into 42 groups in each group and 126 in the Random Allocation software. The format will be in a sealed envelope at the Neuroscience Research Center under the supervision of the inspector. On a daily basis, patients will be studied in groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Carpal tunnel syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Control group: The splint will be prescribed with painkillers (meloxicam 15 mg) and vitamin B1. The splint should be used in neutral position for at least 8 hours a day for 3 months (night and during activity) and painkillers and Vitamin B1 will be taken daily for 6 weeks. Intervention 2: First intervention group: 40 mg of methylprednisolone (depromedrol) in combination with 1% lidocaine will be injected with a 23G needle so that the needle will be placed on the inner side of the Palmaris longus tendon in the distal palmar groove at an angle of 45 ° to the forearm. Intervention 3: Second intervention group: In order to perform laser therapy, the patient is cleaned in a supine position with a cotton swab. It will then be irradiated as much as 4 x 5 cm around the nerve and the laser scanner will be illuminated from a distance of 10 cm. The laser therapy time for each area will be 167 seconds. It should be noted that the laser rotation will be zero, 60% Duty cycle and 100 Hz frequency. Each patient will undergo laser therapy for 3 sessions, one day in between.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
A portion of the study participants' personal data, including demographic data and study outcomes, will be shared after unidentifiable individuals.

When:
The access period will start 3 months after printing.

To whom:
Researchers working in universities.

Conditions:
Researchers working in universities.

Where to obtain:
Address: Poursina Hospital, Namjoo st., Rasht

How to obtain:
A written request for data from the relevant university with the name and academic degree of the researcher

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mozaffar Hosseininezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Namjoo st., Poursina Hospital</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>41937-13194</zip>
        <telephone>+98 13 3332 2444</telephone>
        <email>hosseininezhadm@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mozaffar Hosseininezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Namjoo st., Poursina Hospital</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>41937-13194</zip>
        <telephone>+98 13 3332 2444</telephone>
        <email>hosseininezhadm@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with unilateral or bilateral CTS according to Median Nerve Electrophysiology (EMG-NCV) studies will be enrolled.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of wrist surgery, polyneuropathy, brachial plexopathy or thoracic outlet syndrome
History of thrombocytopenia, platelet disorder, systemic infection, pregnancy and rheumatologic disorders.
Previous injection of cortisone for treatment of CTS
Thenar muscle atrophy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G56.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Carpal tunnel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: The splint will be prescribed with painkillers (meloxicam 15 mg) and vitamin B1. The splint should be used in neutral position for at least 8 hours a day for 3 months (night and during activity) and painkillers and Vitamin B1 will be taken daily for 6 weeks.</i_keyword>
      <i_keyword>First intervention group: 40 mg of methylprednisolone (depromedrol) in combination with 1% lidocaine will be injected with a 23G needle so that the needle will be placed on the inner side of the Palmaris longus tendon in the distal palmar groove at an angle of 45 ° to the forearm.</i_keyword>
      <i_keyword>Second intervention group: In order to perform laser therapy, the patient is cleaned in a supine position with a cotton swab. It will then be irradiated as much as 4 x 5 cm around the nerve and the laser scanner will be illuminated from a distance of 10 cm. The laser therapy time for each area will be 167 seconds. It should be noted that the laser rotation will be zero, 60% Duty cycle and 100 Hz frequency. Each patient will undergo laser therapy for 3 sessions, one day in between.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Symptom severity scale in Boston Carpal Tunnel Syndrome Questionnaire. Timepoint: Measurement of symptom severity at baseline and 6 months later. Method of measurement: Boston Carpal Tunnel Syndrome Questionnaire.</prim_outcome>
      <prim_outcome>Functional status scale in Boston Carpal Tunnel Syndrome Questionnaire. Timepoint: Measurement of functional status at baseline and 6 months later. Method of measurement: Boston Carpal Tunnel Syndrome Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Severity of pain. Timepoint: At baseline and 6 months after intervention. Method of measurement: Visual analog scale.</sec_outcome>
      <sec_outcome>Distal sensory latency. Timepoint: At baseline and 6 months after intervention. Method of measurement: Based on the amount recorded by the EMG-NCV device.</sec_outcome>
      <sec_outcome>Distal motor latency. Timepoint: At baseline and 6 months after intervention. Method of measurement: Based on the amount recorded by the EMG-NCV device.</sec_outcome>
      <sec_outcome>Medical complications. Timepoint: 6 months after intervention. Method of measurement: Based on individual response.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-21</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Namjoo st., Poursina Hospital Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
